RATIONALE: Daily EPIT with Viaskin peanut patch (VP) has been shown to be superior to placebo (PBO) in desensitizing peanut-allergic children aged > _4 years. VP has not been investigated previously in children aged <4 years. METHODS: EPITOPE is an ongoing double-blind, placebo-controlled, randomized Phase 3 trial to assess VP safety and efficacy in peanut-allergic children aged 1-3 years. Here we present the study design and an overview of overall baseline demographics for the first part of the trial (dose selection). Among the inclusion criteria are serum peanut-specific IgE >0.7 kU/L; peanut skin prick test (SPT) largest wheal diameter > _6 mm; and reaction on double-blind, placebo-controlled food challenge to an eliciting dose of < _300 mg peanut protein.
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RESULTS: Peanut-allergic children (n551; 67% male) 1-3 years of age have been enrolled and randomized to treatment with either PBO, 100 mcg VP, or 250 mcg VP. Mean serum peanut-specific IgE at entry was 86.36158.8 kU/L, and mean peanut SPT largest wheal diameter was 13.664.5 mm. Eighty-two percent of subjects were diagnosed previously (as reported by investigator) with food allergy other than peanut (20% milk): 94% atopic dermatitis, 37% allergic rhinitis, and 20% asthma/ bronchial hyperactivity/wheezing. Mean age of subjects at first diagnosis was 1.05 years. Recent Data and Safety Monitoring Board evaluation considered both doses to be well tolerated with a good safety profile. CONCLUSIONS: Age at diagnosis highlights the need for peanut allergy treatment in younger children. Consistent with studies in older children, peanut-allergic subjects in this EPIT clinical trial are highly atopic. RATIONALE: Immunotherapy for food allergy is being investigated as a potential treatment. There is limited data on long-term outcomes of food immunotherapy. METHODS: We contacted 21 subjects who participated in a randomized trial comparing oral versus sublingual peanut immunotherapy (NCT01084174). Follow-up data was collected by telephone questionnaire and/or clinical follow-up 3-8 years after study completion to assess longterm peanut consumption and reaction rates. RESULTS: Of the 21 subjects, 16 were given recommendations for home peanut consumption. Follow-up data was available on 15/16. At last contact, 57% (12/21) were ingesting peanut. 8/12 were regularly eating >1 gram of peanut protein (median 1.9 grams, range: 1 to 4.4) and 4 were eating <1 gram (1 trace amounts only, range: trace-0.75). Over the last 12 months of follow-up, the longest time without eating peanut ranged from 2-21 days (median 7 days). Symptom frequency with peanut ingestion ranged from never (1/12), rarely (9/12), regularly (1/12), or with most exposures (1/12). Most common symptoms included oral pruritus, lower respiratory issues, and gastrointestinal complaints. Reactions were treated with antihistamines (11/12 subjects), albuterol (5/12), H2 blocker (1/12), or epinephrine (2/12). One individual needed epinephrine for 2 reactions. Exercise and missed doses were the most cited factors associated with reactions. Taste was the most common reason why subjects limited peanut intake, followed by reactions and anxiety. 14/15 continue to carry epinephrine, 8 of whom also have a non-peanut food allergy. CONCLUSIONS: Long-term outcomes of peanut immunotherapy are mixed, with many patients returning to peanut avoidance and/or reporting symptoms with peanut ingestion. Stanford University, Stanford, CA. RATIONALE: Oral immunotherapy (OIT) for individuals with food allergy is often perceived to be unsafe, especially in patients who have received epinephrine in the past. In a multi-allergen OIT clinical trial, we have analyzed whether baseline use of epinephrine is associated with an increased rate of dose-related adverse events during OIT. METHODS: In an ongoing clinical trial, 53 participants aged 4 to 20 years old have completed a phase 2 clinical trial involving OIT with multiple foods. These participants consumed doses over 18 weeks and reported adverse events through an electronic diary. Dose-related adverse event (DRAE) rates for each participant were calculated by dividing the number of DRAEs by the number of doses consumed, and participants were grouped according to history of epinephrine use prior to study enrollment. Mean rates between groups were compared through a t-test. RESULTS: A total of 1112 DRAEs were reported by the participants. Among all the DRAEs, 81.1% were gastrointestinal symptoms, 9.44% were respiratory symptoms, and 5.22% were cutaneous symptoms. The mean DRAE rates were 12.3% for those with (n522) and 21.5% for those without (n531) a history of epinephrine use due to accidental exposure prior to start of OIT (p50.08). CONCLUSIONS: For this sample size, a history of epinephrine use for a food allergen prior to initiating OIT was not associated with higher doserelated adverse event rates. Conducting this analysis with a larger sample size would be of interest for future studies.
